Joël Jean-Louis Besse
Geen lopende functies
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Ignacio Faus | M | - |
NFL Biosciences SAS
NFL Biosciences SAS BiotechnologyHealth Technology NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France. | 3 jaar |
Axel Ullrich | M | - |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
François Cadène | M | - |
Pharma Group Santé SAS
Pharma Group Santé SAS Medical DistributorsDistribution Services Pharma Group Santé SAS develops pharmaceutical dispensation solutions. It offers training and product promotion services. The company was founded by François Cadène in 2000 and is headquartered in Marseille, France. | 24 jaar |
Yannick Plétan | M | - |
NFL Biosciences SAS
NFL Biosciences SAS BiotechnologyHealth Technology NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France. | 3 jaar |
Francis Ahner | M | - |
NFL Biosciences SAS
NFL Biosciences SAS BiotechnologyHealth Technology NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France. | 3 jaar |
Michel Huc | M | - |
NFL Biosciences SAS
NFL Biosciences SAS BiotechnologyHealth Technology NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France. | 3 jaar |
Johannes Bange | M | - |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
Junichi Fukute | M | - |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
Esther Zwick | F | - |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
Mauricio Redondo | M | - |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Duitsland | 5 | 50.00% |
Frankrijk | 5 | 50.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Joël Jean-Louis Besse
- Persoonlijk netwerk